メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
岡山大学 ホーム
English
日本語
ホーム
プロファイル
研究部門
研究成果
設備
活動
プレス/メディア
受賞
専門知識、名前、または所属機関で検索
Scopus著者プロファイル
岩田 健宏
助教
,
岡山大学病院
h-index
554
被引用数
13
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
2017
2024
年別の研究成果
概要
フィンガープリント
ネットワーク
研究成果
(48)
類似のプロファイル
(9)
フィンガープリント
Takehiro Iwataが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Medicine and Dentistry
Systematic Review
100%
Meta-Analysis
88%
Transitional Cell Carcinoma
62%
Cystectomy
52%
Clear Cell Renal Cell Carcinoma
46%
Bladder Cancer
33%
Progression Free Survival
28%
Overall Survival
26%
Hazard Ratio
26%
Screening Cultures
25%
Urinary Tract
25%
Pembrolizumab
25%
Prostate Biopsy
25%
Prostate Cancer
25%
Urokinase
25%
Biochemical Recurrence
23%
Upper Urinary Tract
22%
Prostatitis
18%
Clinical Trial
18%
Kidney Metastasis
17%
Randomized Controlled Trial
17%
Prostatectomy
17%
Prognostic Factor
16%
Diagnosis
15%
Nephrectomy
15%
Metastatic Carcinoma
15%
Quality of Life
14%
Urinary Diversion
13%
Neoplasm
13%
Extracorporeal
13%
Blood Transfusion
13%
Recurrence Free Survival
12%
Alpha-Linolenic Acid
12%
Antiinfective Agent
12%
Peroperative Complication
12%
Local Therapy
12%
Fumarate Hydratase
12%
Adjuvant Radiotherapy
12%
Neuroendocrine Differentiation
12%
Gonadorelin Antagonist
12%
Pathogen
12%
Kidney Autotransplantation
12%
Silver Nitrate
12%
Germinoma
12%
Emphysematous Pyelonephritis
12%
Non Muscle Invasive Bladder Cancer
12%
Androgen Therapy
12%
Ureteroscopy
12%
Prostate Adenocarcinoma
12%
Diagnostic Performance
12%
Pharmacology, Toxicology and Pharmaceutical Science
Transitional Cell Carcinoma
62%
Pembrolizumab
37%
Progression Free Survival
35%
Overall Survival
33%
Non Muscle Invasive Bladder Cancer
25%
Urokinase
25%
Bladder Cancer
23%
Cisplatin
22%
Chemotherapy
22%
Gemcitabine
20%
Adverse Event
19%
Clinical Trial
18%
Renal Cell Carcinoma
17%
Recurrence Free Survival
14%
Neoplasm
14%
Malignant Neoplasm
13%
Receptor
13%
Kidney Cancer
12%
Lactobacillus
12%
First-Line Chemotherapy
12%
Prostate Cancer
12%
Inflammation
12%
Proton Pump Inhibitor
12%
Cefditoren Pivoxil
12%
Germ Cell Tumor
12%
Intravaginal Administration
12%
Vagina Flora
12%
Ethanol
12%
Cystitis
12%
Paclitaxel
12%
Gonadorelin Antagonist
12%
Antacid Agent
12%
Endocrine Therapy
12%
Immune Checkpoint Inhibitor
9%
Histamine H2 Receptor Antagonist
8%
Kidney Metastasis
8%
Cancer Specific Survival
7%
Survival Time
7%
Globulin
6%
Biochemical Recurrence
6%
Plasminogen Activator Inhibitor 1
6%
Recurrent Disease
5%
Primary Tumor
5%
Keyphrases
Robot-assisted Radical Cystectomy
25%
Open Radical Cystectomy
25%
Meta-analysis
25%
Systematic Meta-analysis
25%
Oncological Outcomes
14%
Prognostic Factors
12%
Ga-PSMA
12%
Urokinase Plasminogen Activator System
12%
PSMA-11
12%
Salvage Lymph Node Dissection
12%
Unfit Patients
12%
Robot-assisted
12%
Renal Cell Carcinoma
12%
Baseline Tumor Size
12%
Inflammation-based Prognostic Score
12%
Neuroendocrine Differentiation
12%
Fumarate Hydratase
12%
Fumarate Hydratase-deficient Renal Cell Carcinoma
12%
Sarcomatoid Differentiation
12%
Testosterone Recovery
12%
Advanced Renal Cancer
12%
Radical Prostatectomy
12%
Polycystic
12%
Modified Glasgow Prognostic Score (mGPS)
12%
Cefditoren pivoxil
12%
Primary Urethral Cancer
12%
Primary Urethral Carcinoma
12%
Prostate Carcinoma
12%
Urinary Bladder Cancer
12%
Bladder Tuberculosis
12%
Prostate Cancer Survivors
12%
Ipilimumab
12%
Gonadotropin-releasing Hormone Antagonist
12%
Nivolumab
12%
Urokinase-type Plasminogen Activator System
12%
Literature Review Analysis
12%
Screen Media
12%
Rectal Culture
12%
Nonmetastatic Prostate Cancer
12%
Bacterial Screening
12%
Muscular Development
12%
Trans Men
12%
Body Composition Changes
12%
Randomized Controlled Trial
9%
Ureterorenoscopy
7%
4-cycle
6%
Large Baseline
5%
Microbiological Efficacy
5%
